breathing system News
-
Deadly Fungal Pathogen Appears to be Developing Drug Resistance
Clinical Infectious Diseases recently published a study that discovered azole-resistance markers in 75% of a small group of aspergillosis patients who had not previously been treated with an azole. Although the study group was small, the findings appear to indicate that there is a growing dissemination of drug-resistant strains of Aspergillus fungi. Azole antifungal agents are a common option ...
-
Healthcare Facilities need to be Aware of Microbial Pathogens
Countless people live productive and fulfilling lives with immune systems that are weakened due to inherited genetic defects, physical conditions, illnesses, past medical procedures or because of prescription drugs taken for various reasons. These individuals need to be especially aware of common microbial pathogens that are often found all around us. These pathogens may include various ...
-
Ionicon PTR-TOF instruments deployed for COVID-19 detection in breath
SARS-CoV-2 currently has the world in its grasp. A quick, non-invasive test to identify an infection would be a tremendous step forward. There is a high probability that this disease can be detected in the exhaled breath but also monitoring the impact of treatment or medication in exhaled breath is highly relevant. IONICON PTR-TOF systems have become the de-facto standard for real-time breath ...
-
U.S. EPA determines Phoenix dust storms not solely responsible for poor air quality
The U.S. Environmental Protection Agency (EPA) today announced that it rejected Arizona"s claim that dust storms caused the high pollution readings in Phoenix in 2008, a decision which could have significant implications for the State. Under the Clean Air Act, states must submit plans showing the EPA how the State will meet air quality standards for certain pollutants. Arizona is currently not ...
-
IONICON PTR-TOF instruments deployed for COVID-19 detection in breath
There is a high probability that this disease can be detected in the exhaled breath but also monitoring the impact of treatment or medication is highly relevant. Sampling exhaled breath is non-invasive and simple. But the analysis is the challenge: Several hundred volatile compounds have so far been identified in exhaled breath and their range of concentrations, typically in the ...
-
Enalare Therapeutics Files New Patent Application for Lead Product ENA-001 - Potentially Extending Global Exclusivity Through 2042
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions, announced today that it has filed a Provisional Patent Application with the United States Patent and Trademark Office on its lead product ENA-001 and related compounds for the reversal of respiratory depression from non-opioid ...
-
Enalare Therapeutics Announces First Subject Dosed With Lead Product ENA-001 in a Propofol-Induced Respiratory Depression Study
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has dosed the first subject with its lead product ENA-001 in a propofol-induced respiratory depression study. This study aims to demonstrate the ability of ENA-001 to reverse respiratory depression induced ...
-
Enalare Files Additional Patent Application for Lead Compound ENA-001 - Enhancing Potential Global Exclusivity Through 2042
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has filed a Provisional Patent Application with the United States Patent and Trademark Office directed to parenteral formulations of ENA-001 and related compounds. The patent application encompasses the ...
-
NIH, ONC, and EPA award $100,000 to winner of health and technology challenge
The challenge was held by the National Institutes of Health, the Office of the National Coordinator for Health Information Technology (ONC) of the U.S. Department of Health and Human Services, and the U.S. Environmental Protection Agency (EPA). New technology that creates a personal, portable, and wearable air pollution sensor, developed under the My Air, My Health Challenge, was announced today ...
-
Enalare Therapeutics Receives a National Institutes of Health (NIH) Grant Award
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). Funding from the grant will be used to further the development of ENA001, Enalare's ...
-
Enalare Therapeutics Receives Rare Pediatric Disease Designation for Lead Compound ENA-001 for the Treatment of Apnea of Prematurity
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions, announced today that the Food and Drug Administration (FDA) has granted it's lead compound, ENA-001, rare pediatric disease designation for the treatment of Apnea of Prematurity. Enalare is planning to develop this unique agnostic ...
-
Enalare Therapeutics Announces Positive Topline Results With ENA001 in a Propofol Induced Respiratory Depression Study
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has completed a propofol induced respiratory depression study with its lead compound ENA001, having achieved the targeted primary endpoint. The objective of the study was to demonstrate the ability of ENA001 ...
-
EPA Strengthens Ozone Standards to Protect Public Health/Science-based standards to reduce sick days, asthma attacks, emergency room visits, greatly outweigh costs
Based on extensive scientific evidence on effects that ground-level ozone pollution, or smog, has on public health and welfare, the U.S. Environmental Protection Agency (EPA) has strengthened the National Ambient Air Quality Standards (NAAQS) for ground-level ozone to 70 parts per billion (ppb) from 75 ppb to protect public health. The updated standards will reduce Americans’ exposure to ...
-
Meet the Molds - Important aeroallergens in allergy testing
Despite being defined more than 100 years ago; atmospheric molds have remained undervalued as an important aeroallergen in allergy testing. Of the estimated number of more than 1 million different fungal species, approximately 80 species have been linked with respiratory allergy. However, epidemiologic studies have suggested that the prevalence of allergies to molds is less than 3% in an allergic ...
-
Enalare Therapeutics Receives an Additional Award Worth Up to $50 Million From BARDA, Expanding Its Partnership in Development of ENA-001
The Funding Will Accelerate Development of an Intramuscular Formulation of ENA-001, a Novel Agnostic Respiratory Stimulant, for the Potential Treatment of Community Drug Overdose and as a Medical Countermeasure for Mass Casualty Events. The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States Enalare Therapeutics ...
-
Cairn Diagnostics Launches FDA-Approved Carbon-13 Spirulina Gastric Emptying Breath Test For Gastroparesis
Cairn Diagnostics, formerly known as Advanced Breath Diagnostics (ABDiagnostics), has launched the 13C-Spirulina Gastric Emptying Breath Test (GEBT). The GEBT is intended for measurements of the rate of solid-phase gastric emptying and as an aid in the diagnosis of delayed gastric emptying (gastroparesis) in symptomatic adults. The Cairn GEBT was approved by the U.S. Food and Drug Administration ...
-
Enalare Therapeutics Receives Orphan Drug Designation From the U.S. FDA on ENA-001 for the Treatment of Apnea of Prematurity (AoP)
ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease designation for the Treatment of AoP by the FDA, with eligibility for a priority review voucher (PRV). The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose. ...
-
Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant
ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity Approval for post-operative respiratory depression expected in 2026 and community drug overdose thereafter ENA-001 works peripherally by inhibiting Big Potassium (BK) ion channels in the carotid bodies, which are located in the neck. By inhibiting these channels, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you